Abstract:Key PointsAll malignant gliomas share an important feature: aggressive invasiveness. This invasion is largely contained within the cranium, typically without metastasis to other organs.Glioma cells secrete brevican and tenascins into the extracellular space, promoting migration. They also release proteases, including membrane type matrix metalloproteinase 1 (MMP1), MMP2 and MMP9, to degrade the dense extracellular matrix, which provides a path for migration.Bradykinin is produced in vascular endothelial cells and promotes the association of human glioma cells with blood vessels. Inhibition of bradykinin receptors on glioma cells with icatibant, a US Food and Drug Administration (FDA)-approved drug, significantly reduces glioma cell migration and association with blood vessels.Glioma cells undergo hydrodynamic shape and volume changes, changing volume by up to 33% to fit through the narrow extracellular spaces of the brain. Cell volume changes are accomplished by the efflux of salt though K+ and Cl− channels, leading to subsequent osmotic release of cytoplasmic water.The close association of glioma cells with the vasculature disrupts the interaction between astrocytic endfeet and endothelial cells. This in turn leads to a breakdown of the blood–brain barrier and abolishes the neurovascular unit where astrocytes locally regulate blood flow.Glutamate is released from glioma cells through system xc−. This glutamate acts in an autocrine and paracrine manner to promote glioma migration and proliferation, kills peritumoural neurons through excitotoxicity and increases neuronal excitability, leading to seizures. Sulfasalazine, an FDA-approved drug, inhibits glioma-induced seizures by blocking glutamate released through system xc−.Glioma cells use the same extracellular routes for migration as immature neurons, repurpose ion channels to undergo volume changes during migration and release excessive amounts of glutamate, culminating in seizures and neuronal death. Understanding this unique biology of gliomas through a neurocentric perspective reveals brain-specific therapeutic targets that have thus far not been exploited.

Molecular Biological Mechanism of Glioma Invasion

A Feedforward Mechanism Mediated by Mechanosensitive Ion Channel PIEZO1 and Tissue Mechanics Promotes Glioma Aggression.

Molecular Mechanisms and Clinical Challenges of Glioma Invasion

Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives

Intrinsic and Microenvironmental Drivers of Glioblastoma Invasion

Molecular and Microenvironmental Determinants of Glioma Stem-Like Cell Survival and Invasion

Tumor Cell Invasion in Glioblastoma

The role of lysosomal peptidases in glioma immune escape: underlying mechanisms and therapeutic strategies

Advancing precision medicine in gliomas through single-cell sequencing: unveiling the complex tumor microenvironment

Molecular mechanisms of microRNAs in glioblastoma pathogenesis

Molecular mechanism of Notch signaling with special emphasis on microRNAs: Implications for glioma

Tumor Microenvironment in Glioma Invasion

Function of Long Noncoding RNAs in Glioma Progression and Treatment Based on the Wnt/β-Catenin and PI3K/AKT Signaling Pathways

Molecular Mechanisms of Treatment Resistance in Glioblastoma

The biology and mathematical modelling of glioma invasion: a review

Glioblastoma invasion relies on actomyosin contractility and metalloproteinase activity

The pathogenesis mechanism and potential clinical value of lncRNA in gliomas

The Pathobiology of Glioma Tumors

Recent Advances in Understanding Mechanisms of TGF Beta Signaling and Its Role in Glioma Pathogenesis

Mechanisms of Long Non-Coding RNAs in Biological Characteristics and Aerobic Glycolysis of Glioma

A neurocentric perspective on glioma invasion